Proteome Sciences said this week it has signed an agreement with Siena Biotech making it the preferred supplier of protein and peptide biomarker services for Siena's drug development research.
The first project under the agreement calls for Proteome Sciences to provide a detailed analysis of post-translational modifications on a neurological disease-related protein. Such maps, the company noted in a statement, are "often used to confirm proof of disease mechanism and/or mode of action of new targeted therapeutics providing information to suppose go/no-go decisions in early drug development."
Siena's drug development efforts are focused in the neurodegenerative diseases and oncology spaces, both of which have been areas of concentration for Proteome Sciences. The company offers two SRM-MS assays for Alzheimer's research – its AD-TMT-SRM assay, which measures levels of nine Alzheimer's biomarkers in serum, and an assay for measuring levels of phosphorylated tau protein in brain tissue – and has recently begun moving into the clinical oncology market, signing agreements for cancer research with the Moffitt Cancer Center of Tampa, Fla., and the Buck Institute for Research on Aging in Novato, Calif. (PM 07/22/2011).
Proteome Sciences will be doing the Siena PTM work on a Thermo Scientific Orbitrap Velos, the company said.
Financial and other terms of the agreement were not disclosed.